Literature DB >> 8709307

Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.

Y Goto1, M Ohori, A Arakawa, M W Kattan, T M Wheeler, P T Scardino.   

Abstract

PURPOSE: We assessed the ability of diagnostic tests to distinguish clinically unimportant cancers.
MATERIALS AND METHODS: We correlated T stage (based on digital examination and ultrasound), prostate specific antigen (PSA), PSA density and pathological features of cancer in systematic biopsy specimens with features of cancer in 170 radical prostatectomy specimens. Clinically unimportant cancers were defined as small (0.5 cm.3 or less), well or moderately differentiated and confined to the prostate.
RESULTS: Of the patients 10% had an unimportant cancer. On logistic regression analysis the 2 significant predictors were maximum length of cancer in any core and PSA density. Of 12 patients with maximum cancer length 2 mm. or less and PSA density less than 0.1., 75% had an unimportant cancer compared to 5% of the remaining 158 (p < 0.0005).
CONCLUSIONS: Quantitative analysis of systematic biopsy specimens combined with PSA density provides valuable staging information and helps to identify cancers of low biological potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709307

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Comparison of two commonly used methods in measurement of cancer volume in prostate biopsy.

Authors:  Viharkumar Patel; Samuel Hubbard; Wei Huang
Journal:  Int J Clin Exp Pathol       Date:  2020-04-01

2.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

Review 3.  [Selection criteria for the expected management of localised prostate cancer].

Authors:  M Graefen; G Salomon; E Currlin; C Eichelberg; T Schlomm; H Huland
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

4.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

5.  Number of prostate cancer risk alleles may identify possibly 'insignificant' disease.

Authors:  Brian T Helfand; Stacy Loeb; Donghui Kan; William J Catalona
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

6.  Development and Evaluation of an Actuated MRI-Compatible Robotic System for MRI-Guided Prostate Intervention.

Authors:  Axel Krieger; Sang-Eun Song; Nathan B Cho; Iulian Iordachita; Peter Guion; Gabor Fichtinger; Louis L Whitcomb
Journal:  IEEE ASME Trans Mechatron       Date:  2011-10-17       Impact factor: 5.303

7.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

Review 8.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 9.  [Active surveillance for prostate cancer].

Authors:  M Graefen; S Ahyai; R Heuer; G Salomon; T Schlomm; H Isbarn; L Budäus; H Heinzer; H Huland
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

10.  Focal treatment of prostate cancer with vascular-targeted photodynamic therapy.

Authors:  Scott E Eggener; Jonathan A Coleman
Journal:  ScientificWorldJournal       Date:  2008-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.